**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was done. Co-authors will be added in a separate section.**
Giuseppe Vergaro
Health Science Interdisciplinary Center, Scuola Superiore Sant'Anna; Pisa; ITALY

**Main Body of the Abstract**
Background: Recent studies have explored the diagnostic applications of [18F]-florbetaben PET/CT in cardiac light chain (AL) amyloidosis, yielding promising results. However, information on [18F]-florbetaben PET/CT as a tool for risk stratification is still missing. We aimed to examine the prognostic value of [18F]-florbetaben uptake in patients with cardiac AL amyloidosis (AL-CA).
Methods: Consecutive patients with biopsy-proven AL-CA received clinical and biohumoral evaluation, and were submitted to [18F]-florbetaben PET/CT with a 60-minute dynamic acquisition. Whole-heart static images were retrospectively reconstructed from the dynamic listmode acquisition between 50 and 60 min (late static). Late mean standardized uptake (SUVmean) was calculated. Patients were then followed-up for the end-point of all-cause mortality.
Results: 40 patients (age 68±10 years; 73% males) with AL-CA were recruited. During the follow-up, 23 patients (58%) died. The best prognostic SUVmean cut-off was calculated at 3.31 with Youden test after ROC analysis. Patients with high SUVmean (>3.31, n=25) had a higher  risk of death at Cox regression analysis (p=0.004), as also shown by Kaplan Meier curves in Figure 1. This association was maintained after adjustment for age, sex and 2012 MAYO staging system(p=0.030; HR 2.930, CI 0.196-3.865). At linear regression analysis, SUVmean was associated with hs-Troponin T (r=0.420, p=0.007) but not with N-terminal fragment of B-type natriuretic peptide (NT-proBNP, r=0.278, p=0.100).
Conclusions: High cardiac [18F]-florbetaben PET/CTuptake (SUVmean >3.31) may indicate a greater tissue damage (as reflected by higher troponin levels), and is an independent predictor of death in patients with AL-CA.  [18F]-florbetaben PET/CT holds both diagnostic and prognostic value.



**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was done. Co-authors will be added in a separate section.**
Giuseppe Vergaro
Health Science Interdisciplinary Center, Scuola Superiore Sant'Anna; Pisa; ITALY

**Main Body of the Abstract**
**Background:** Recent studies have explored the diagnostic applications of [18F]-florbetaben PET/CT in cardiac light chain (AL) amyloidosis, yielding promising results. However, information on [18F]-florbetaben PET/CT as a tool for risk stratification is still missing. We aimed to examine the prognostic value of [18F]-florbetaben uptake in patients with cardiac AL amyloidosis (AL-CA).
**Methods:** Consecutive patients with biopsy-proven AL-CA received clinical and biohumoral evaluation, and were submitted to [18F]-florbetaben PET/CT with a 60-minute dynamic acquisition. Whole-heart static images were retrospectively reconstructed from the dynamic listmode acquisition between 50 and 60 min (late static). Late mean standardized uptake (SUVmean) was calculated. Patients were then followed-up for the end-point of all-cause mortality.
**Results:** 40 patients (age 68±10 years; 73% males) with AL-CA were recruited. During the follow-up, 23 patients (58%) died. The best prognostic SUVmean cut-off was calculated at 3.31 with Youden test after ROC analysis. Patients with high SUVmean (>3.31, n=25) had a higher  risk of death at Cox regression analysis (p=0.004), as also shown by Kaplan Meier curves in Figure 1. This association was maintained after adjustment for age, sex and 2012 MAYO staging system(p=0.030; HR 2.930, CI 0.196-3.865). At linear regression analysis, SUVmean was associated with hs-Troponin T (r=0.420, p=0.007) but not with N-terminal fragment of B-type natriuretic peptide (NT-proBNP, r=0.278, p=0.100).
**Conclusions:** High cardiac [18F]-florbetaben PET/CTuptake (SUVmean >3.31) may indicate a greater tissue damage (as reflected by higher troponin levels), and is an independent predictor of death in patients with AL-CA.  [18F]-florbetaben PET/CT holds both diagnostic and prognostic value.



[18F]-Florbetaben PET/CT holds prognostic value in cardiac AL amyloidosis PB105 (#194)

We invite you to attend the XIX International Symposium on Amyloidosis to be held in Rochester, MN.

This symposium is organized as a hybrid meeting (with the focus on in-person) held from Sunday, May 26 through Thursday, May 30, 2024.

Together with the ISA Board and members of Mayo Clinic, a very attractive scientific hybrid program is being planned. The program will cover a variety of types of systemic amyloidosis: ATTR (hereditary and wild-type), AL (light-chain), AA and less frequent forms. There will be key lectures, specific symposia including those company sponsored, oral presentations and poster sessions of accepted abstracts.

COURSE DESCRIPTION
This program will provide a comprehensive review of state-of-the-art education in systemic amyloidosis: basic science, pathophysiology, diagnosis, current and emerging treatments. Scientific presentations will include competitive oral and poster abstracts. The rapid evolution of scientific discovery and expanding treatment options has created tremendous interest in the field and this meeting will fill and important gap in educating scientists and clinicians.